Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader

BURLINGTON, Mass., Jan. 22, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the company's total Series B financing to$77 million,...

2026-01-22 20:00 4199

Telangana (India) Sets Global Ambition with Next-Gen Life Sciences Policy 2026-30

* Positioning Telangana among the world's top five life sciences clusters by 2030 * Targets USD 25 billion in investments * Shifts focus from scale-led manufacturing to innovation-driven, value creation DAVOS, Switzerland, Jan. 22, 2026 /PRNewswire/ -- The Government of Telangana, India tod...

2026-01-22 09:00 5040

Telangana (India) Sets Global Ambition with Next-Gen Life Sciences Policy 2026-30

Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China

HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced th...

2026-01-21 19:08 6097

Samsung Biologics reports fourth quarter and fiscal year 2025 financial results

* Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion * Maintained momentum through consistent operational performance and robust client demand * Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale INC...

2026-01-21 15:20 4536

Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.

IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ -- Gene Solutions , a global biotechnology company, andPangea Laboratory

2026-01-21 09:00 4852

Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

* Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insi...

2026-01-21 08:15 5509

Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

* Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases * Enhances strong global regulatory momentum, ...

2026-01-21 06:00 4659

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broaden...

2026-01-21 01:55 3708

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughput Kinase Inhibitor Screening

HOUSTON, Jan. 20, 2026 /PRNewswire/ -- Sino Biological, Inc. is proud to announce the launch of its innovativeSwiftFluo® TR-FRET Kinase Assay Kits , a ready-to-use, high-performance solution designed to accelerate kinase...

2026-01-20 23:00 4444

LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders

BEIJING, Jan. 20, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics f...

2026-01-20 20:00 6194

GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation

SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- On January 9th, GENEIII reaffirmed its global leadership in ergothioneine production and scientific validation at the "Research Without Borders • Tracing the Source with GENEIII" Global Evidence-Based Journey. GENEIII joined forces with core partners to v...

2026-01-20 18:09 3950

GENEIII Sets the Global Benchmark for Ergothioneine with Pharmaceutical-Grade Purity and Human Clinical Validation

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent t...

2026-01-20 17:00 3896

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will acquire world-wide rights to use ALT-B4, Alteog...

2026-01-20 15:55 4446

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights * Full-year (FY) 2...

2026-01-20 15:16 7061

AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities

HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative 20-valent pneumococcal conjugate vaccine, which has recently received clinical trial approval from the ...

2026-01-20 08:23 3263

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (...

2026-01-20 06:15 3650

Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialogue with Peter Nobel, Chairman of the Nobel Sustainability Trust, Declaring Global Leadership as a Pioneer of Medical Sustainability

TOKYO, Jan. 20, 2026 /PRNewswire/ -- Sakai Clinic 62 (Location: Shibuya-ku, Tokyo; Founder & Medical Director: Mari Sakai) announces that Dr. Mari Sakai held a dialogue with Mr. Peter Nobel, Chairman of the Nobel Sustainability Trust (NST), to discuss the international promotion of sustainability...

2026-01-20 00:00 4744

Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialogue with Peter Nobel, Chairman of the Nobel Sustainability Trust, Declaring Global Leadership as a Pioneer of Medical Sustainability

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions

Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data CHENGDU, China, Jan. 19, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechno...

2026-01-19 21:00 3354

Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center f...

2026-01-19 19:24 4426

D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002

SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: * D3S‑003 — ...

2026-01-19 09:00 3837

1 2 3 456 7 8 ... 339